Albireo Pharma, Inc. Common Stock

Albireo Pharma, Inc. (www.albireopharma.com) is a biopharmaceutical company focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay (odevixibat), developed for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) and elobixibat, developed for the treatment of chronic constipation, a Phase I product candidate and multiple preclinical candidates. Bylvay is also in Phase III development for the treatment of biliary atresia and Alagille syndrome (ALGS). It also has a preclinical program in adult liver and viral diseases. Its lead preclinical candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT). Its lead candidate for adult viral and liver diseases is A2342, an oral systemic sodium-taurocholate co-transporting peptide (NTCP) inhibitor.

• Albireo Pharma, Inc. Common Stock